Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer

Molecular Carcinogenesis

Volumn 55, Issue 5, 2016, Pages 977-990

  Liu, Hui ^a,b   Liu, Lanxin ^b   Holowatyj, Andreana ^b   Jiang, Yuanyuan ^b   Yang, Zeng Quan ^b,c  

^a JILIN UNIVERSITY   (China)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Copy number alteration; Gene amplification; Histone lysine demethylase; KDM2A

Indexed keywords

DNA; F BOX PROTEIN; HISTONE DEMETHYLASE; HISTONE DEMETHYLASE KDM2A; HISTONE DEMETHYLASE KDM5B; MESSENGER RNA; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ISOPROTEIN; KDM2A PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER SURVIVAL; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; BREAST TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SURVIVAL ANALYSIS; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; F-BOX PROTEINS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; PROTEIN ISOFORMS; SURVIVAL ANALYSIS;

EID: 84937774684     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22341     Document Type: Article

References (68)

1. Labbe RM, Holowatyj A, Yang ZQ. Histone lysine demethylase (KDM) subfamily 4: Structures, functions and therapeutic potential. Am J Transl Res 2014; 6:1-15.
2. Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119:941-953.
3. Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 2012; 13:297-311.
4. Johansson C, Tumber A, Che KH, et al. The roles of Jumonji-type oxygenases in human disease. Epigenomics 2014; 6:89-120.
5. Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 2006; 7:715-727.
6. Klose RJ, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 2007; 8:307-318.
7. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005; 6:838-849.
8. Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: Intricacy of writing and reading a single epigenetic mark. Mol Cell 2007; 25:15-30.
9. Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: Establishment, regulation, and biological impact. Mol Cell 2012; 48:491-507.
10. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA: J Am Med Assoc 2006; 295:2492-2502.
11. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics: Targ Therap 2012; 6:289-297.
12. Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61-70.
13. Northcott PA, Nakahara Y, Wu X, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009; 41:465-472.
14. Vinatzer U, Gollinger M, Mullauer L, Raderer M, Chott A, Streubel B. Mucosa-associated lymphoid tissue lymphoma: Novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin Cancer Res 2008; 14:6426-6431.
15. Italiano A, Attias R, Aurias A, et al. Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C. Cancer Genet Cytogenet 2006; 167:122-130.
16. Suikki HE, Kujala PM, Tammela TL, van Weerden WM, Vessella RL, Visakorpi T. Genetic alterations and changes in expression of histone demethylases in prostate cancer. Prostate 2010; 70:889-898.
17. Liu G, Bollig-Fischer A, Kreike B, et al. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 2009; 28:4491-4500.
18. Rui L, Emre NC, Kruhlak MJ, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 2010; 18:590-605.
19. Luo W, Chang R, Zhong J, Pandey A, Semenza GL. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci USA 2012; 109:E3367-E3376.
20. Yang ZQ, Imoto I, Fukuda Y, et al. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res 2000; 60:4735-4739.
21. Hou J, Wu J, Dombkowski A, et al. Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. Am J Transl Res 2012; 4:247-256.
22. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141:69-80.
23. Young LC, McDonald DW, Hendzel MJ. Kdm4b histone demethylase Is a DNA damage response protein and confers a survival advantage following γ-irradiation. J Biol Chem 2013; 288:21376-21388.
24. Black JC, Manning AL, Van Rechem C, et al. KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell 2013; 154:541-555.
25. Young LC, Hendzel MJ. The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression1. Biochem Cell Biol 2012; 91:369-377.
26. Yang ZQ, Streicher KL, Ray ME, Abrams J, Ethier SP. Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res 2006; 66:11632-11643.
27. Forozan F, Veldman R, Ammerman CA, et al. Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 1999; 81:1328-1334.
28. Gao JJ, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6, p. pl1.
29. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2:401-404.
30. Albertson DG. Gene amplification in cancer. Trends Genet 2006; 22:447-455.
31. Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet 2003; 34:369-376.
32. Kaneko S, Bonasio R, Saldana-Meyer R, et al. Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin. Mol Cell 2014; 53:290-300.
33. Prat A, Karginova O, Parker JS, et al. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat 2013; 142:237-255.
34. Adelaide J, Finetti P, Bekhouche I, et al. Integrated profiling of basal and luminal breast cancers. Cancer Res 2007; 67:11565-11575.
35. Crowder RJ, Phommaly C, Tao Y, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009; 69:3955-3962.
36. Goldman M, Craft B, Swatloski T, et al. The UCSC Cancer Genomics Browser: Update 2013. Nucleic Acids Res 2013; 41:D949-D954.
37. Gatza ML, Silva GO, Parker JS, Fan C, Perou CM. An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat Genet 2014; 46:1051-1059.
38. Fang R, Barbera AJ, Xu Y, et al. Human LSD2/KDM1b/AOF1 regulates gene transcription by modulating intragenic H3K4me2 methylation. Mol Cell 2010; 39:222-233.
39. Katz TA, Vasilatos SN, Harrington E, Oesterreich S, Davidson NE, Huang Y. Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells. Breast Cancer Res Treat 2014; 146:99-108.
40. Defeojones D, Huang PS, Jones RE, et al. Cloning of cdnas for cellular proteins that bind to the retinoblastoma gene-product. Nature 1991; 352:251-254.
41. Lin W, Cao J, Liu J, et al. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci USA 2011; 108:13379-13386.
42. Teng YC, Lee CF, Li YS, et al. Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis. Cancer Res 2013; 73:4711-4721.
43. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 2009; 9:773-784.
44. Di Croce L, Helin K. Transcriptional regulation by Polycomb group proteins. Nat Struct Mol Biol 2013; 20:1147-1155.
45. Ren G, Baritaki S, Marathe H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res 2012; 72:3091-3104.
46. Lu PJ, Sundquist K, Baeckstrom D, et al. A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem 1999; 274:15633-15645.
47. Yamane K, Tateishi K, Klose RJ, et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell 2007; 25:801-812.
48. Catchpole S, Spencer-Dene B, Hall D, et al. PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells. Int J Oncol 2011; 38:1267-1277.
49. Yamamoto S, Wu Z, Russnes HG, et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell 2014; 25:762-777.
50. Riaz M, van Jaarsveld MT, Hollestelle A, et al. MiRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res 2013; 15:R33.
51. Kawazu M, Saso K, Tong KI, et al. Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PLoS One 2011; 6:e17830.
52. Yang J, Jubb AM, Pike L, et al. The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res 2010; 70:6456-6466.
53. Shi L, Sun L, Li Q, et al. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci USA 2011; 108:7541-7546.
54. Berry WL, Janknecht R. KDM4/JMJD2 histone demethylases: Epigenetic regulators in cancer cells. Cancer Res 2013; 73:2936-2942.
55. Blackledge NP, Zhou JC, Tolstorukov MY, Farcas AM, Park PJ, Klose RJ. CpG islands recruit a histone H3 lysine 36 demethylase. Mol Cell 2010; 38:179-190.
56. Tsukada Y, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006; 439:811-816.
57. Cheng Z, Cheung P, Kuo AJ, et al. A molecular threading mechanism underlies Jumonji lysine demethylase KDM2A regulation of methylated H3K36. Genes Dev 2014; 28:1758-1771.
58. Lu T, Jackson MW, Wang B, et al. Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci USA 2010; 107:46-51.
59. Lu T, Jackson MW, Singhi AD, et al. Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. Proc Natl Acad Sci USA 2009; 106:16339-16344.
60. Rizwani W, Schaal C, Kunigal S, Coppola D, Chellappan S. Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells. PLoS One 2014; 9:e100888.
61. Wagner KW, Alam H, Dhar SS, et al. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest 2013; 123:5231-5246.
62. Huang Y, Liu Y, Yu L, et al. Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer. Tumour Biol 2015; 36:271-278.
63. Levi L, Lobo G, Doud MK, et al. Genetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis. Cancer Res 2013; 73:4770-4780.
64. Tilch E, Seidens T, Cocciardi S, et al. Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. Breast Cancer Res Treat 2014; 143:385-392.
65. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014; 14:455-467.
66. Salhia B, Kiefer J, Ross, et al. Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS One 2014; 9:e85448.
67. Chen M, Manley JL. Mechanisms of alternative splicing regulation: Insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 2009; 10:741-754.
68. Zhang J, Manley JL. Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov 2013; 3:1228-1237.